Dartmouth researchers explored the type and number of connections in transcription factor networks (TFNs) to evaluate the role assortativity plays on robustness in a study published in PLOS Computational Biology in August. The study found that the assortativity signature contributes to a network’s resilience against mutations.
Dartmouth researchers are exploring ways to use nano particles to wake up the immune system so it recognizes and attacks invading cancer cells.
Becker’s Hospital Review included Dartmouth-Hitchcock Medical Center in its 2014 list of “100 Hospitals and Health Systems with Great Oncology Programs.” Organizations included on this year’s list are considered to be leaders in quality patient care, cancer outcomes and research.
A recent study evaluating HER2 testing in a large cohort of women with breast cancer found important limitations in the conventional way HER2 testing is performed in the U.S. and internationally.
Dartmouth will serve as a Lead Academic Participating Site in the National Cancer Institute’s (NCI) new National Clinical Trials Network (NCTN), which is intended to improve the speed and efficiency of conducting cancer clinical trials.
Upcoming EventsThis page may link to PDF files. Use this link to download Adobe Reader if needed.